TAPI-1

TAPI-1 (TNF-alpha Protease Inhibitor-1) is a broad-spectrum small molecule inhibitor of matrix metalloproteinases (MMPs) and ADAM (A Disintegrin And Metalloproteinase) family enzymes. It is most notably characterized as a potent inhibitor of TACE (TNF-alpha converting enzyme), also known as ADAM17. By blocking the catalytic activity of ADAM17, TAPI-1 prevents the proteolytic ectodomain shedding of various cell-surface proteins, including TNF-alpha, L-selectin, and the IL-6 receptor (sIL-6R). In oncological research, particularly in pancreatic cancer models, TAPI-1 is used to demonstrate how inhibiting the release of soluble factors like sIL-6R can abrogate autocrine and paracrine signaling pathways that drive tumor cell proliferation and survival. It is primarily utilized as a laboratory research tool rather than a clinical therapeutic candidate.

Other names

TNF-alpha Protease Inhibitor-1TACE Inhibitor I(R)-TAPI-1